Navigation Links
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Date:4/16/2008

retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through its website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to http://www.Sedar.com. For SEDAR filings prior to July 10, 2007 you will find these under the company profile for Global Summit Real Estate Inc. (Old Lorus).


'/>"/>
SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
(Date:12/15/2014)... Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) ... supplier of crop seeds in China , ... fiscal year 2014 ended September 30, 2014, before the market ... will host a teleconference on January 8, 2015, at 8:00 ... time to discuss the results. To participate in the call, ...
(Date:12/13/2014)... - MaRS and Virgin Unite Canada, the non-profit foundation of ... to support Canadian entrepreneurs tackling social and environmental challenges. Today, ... the MaRS Centre to announce the new partnership, which includes ... fund has $1 million in seed capital provided by Virgin ... Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... million, -- Quarterly Net Income Increases 76.5% to ... YORK and HAIKOU, Hainan, China, May 2 /Xinhua-PRNewswire-FirstCall/,-- ... Board: CPHI),which develops, manufactures, and markets generic and ... results,for the first quarter of 2008., ...
... May 2 eResearchTechnology, Inc.,(eRT), (Nasdaq: ... (ECG) collection and interpretation services,announced today that ... and,Chief Executive Officer, and Richard Baron, the ... at the Deutsche Bank 33rd Annual,Healthcare Conference ...
... 2 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), ... for the early,detection of diseases and personalized ... for the first quarter ended March 31,2008., ... of the key milestones,necessary to support the ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 2China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 4China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 5China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 6China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 7China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 8China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 9eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008 2GeneNews Announces First Quarter Results 2GeneNews Announces First Quarter Results 3GeneNews Announces First Quarter Results 4GeneNews Announces First Quarter Results 5GeneNews Announces First Quarter Results 6GeneNews Announces First Quarter Results 7GeneNews Announces First Quarter Results 8
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... June 09, 2009 / b3c newswire / - ... Netherlands Organisation for Applied Scientific Research TNO today announced ... further develop Amarna’s viral gene delivery platform SVac ... for the manufacture, formulation and testing of viral gene ...
... axial complex of sea urchins ( Echinoidea ), an ... that group of marine invertebrates there exists a structural ... in BioMed Central,s open access journal Frontiers in ... structural data available on a given organ in combination ...
... Merck Irving S. Sigal Memorial Award is being presented ... Infectious Disease Initiative at the Broad Institute of MIT ... Medicine at Harvard Medical School. Sponsored by Merck Research ... presented in memory of Irving S. Sigal, who was ...
Cached Biology News:Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Glutathione Agarose Beads 10 ml...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products: